Financial StabilityICCM's recent rights offering was 2x oversubscribed, generating significant gross proceeds that will support its financial stability.
Market PotentialThe ProSense cryoablation procedure, which is minimally invasive, has the potential to replace lumpectomy for the target patient population of approximately 46,000 women in the U.S. annually.
Regulatory ProgressThe FDA Medical Device Advisory Committee Panel gave a favorable recommendation for ICCM's ProSense System, with nine panelists voting in favor, indicating a positive outcome for IceCure.